Encompass Health Corporation filings document the operating results, financing arrangements and governance matters of a public inpatient rehabilitation hospital company. Its Form 8-K reports furnish earnings releases, Regulation FD materials, same-store performance measures and non-GAAP metrics such as adjusted earnings per share, leverage ratio, Adjusted EBITDA and adjusted free cash flow.
Other filings record capital-structure and governance subjects, including the company's credit agreement, revolving credit facility, subsidiary guarantor arrangements, board appointments, committee assignments and director compensation practices. The definitive proxy statement addresses annual meeting proposals, executive compensation, pay-versus-performance disclosure, board structure and stockholder voting matters.
Encompass Health Corp (EHC) insider Patrick W. Tuer, EVP and Chief Operating Officer, reported a sale of 1,020 shares of Encompass Health common stock on 08/27/2025 at a reported price of $123.59 per share. After the transaction, Mr. Tuer beneficially owned 18,846 shares. The Form 4 was signed by an attorney-in-fact, Patrick Darby, on behalf of the reporting person.
Encompass Health Corporation (EHC) Form 144 reports a proposed sale of 1,020 common shares via UBS Financial Services on the NYSE, with an aggregate market value of $126,061.80. The shares were acquired through restricted stock unit vesting in January–February 2023 (individual lots of 218, 290, 233 and 279 shares) and are scheduled for sale on 08/27/2025. The filer certifies no undisclosed material adverse information and provides no reportable sales in the prior three months.
Douglas E. Coltharp, EVP & Chief Financial Officer of Encompass Health Corporation (EHC), reported multiple non‑derivative transactions on 08/21/2025. The filing shows transfers involving common stock: 27,480 shares were disposed of by the reporting person’s spouse and simultaneously 27,480 shares were acquired by an irrevocable trust in which the reporting person is a beneficiary. After these moves the reporting person reports 37,749 shares beneficially owned via spouse and 125,631 shares indirectly held by an irrevocable trust for the benefit of children; the reporting person disclaims beneficial ownership of the spouse‑held shares. The report was signed by an attorney‑in‑fact.
Encompass Health Corporation (EHC) Q2 2025 condensed summary
Net operating revenues for the three months ended June 30, 2025 were $1,457.7 million (up 12.0% vs. Q2 2024) and $2,913.1 million for the six months ended June 30, 2025 (up 11.3% vs. prior year six months). Net income was $184.9 million for Q2 2025 and net income attributable to Encompass Health was $142.1 million for Q2 2025 vs. $114.1 million in Q2 2024. Diluted EPS for the quarter was $1.39. Adjusted EBITDA was $318.6 million for Q2 2025 and $632.2 million for the six months. Operating cash flow for six months was $558.8 million. Cash, cash equivalents, and restricted cash at June 30, 2025 were $137.4 million.
The company operated 168 inpatient rehabilitation hospitals as of June 30, 2025, completed a May 2025 acquisition of a Fort Myers inpatient rehabilitation unit (51% interest) with $19.0 million goodwill recorded, and continued shareholder distributions via repurchases ($56.8 million YTD) and dividends ($35.1 million YTD). Management estimates certain provisions of the One Big Beautiful Bill Act will produce approximately $180 million of current deductions, yielding an estimated $50 million in cash tax savings in 2025. The filing discloses ongoing Medicare Review Choice Demonstration (RCD) non-affirmations in Alabama cycles and other regulatory risks.
Encompass Health Corporation (NYSE: EHC) has published a new Investor Reference Book on June 25, 2025, providing comprehensive insights into the company's operations, strategy, and financial metrics. The document includes details about the company's business outlook, growth strategy, and operational initiatives.
The filing provides important context around non-GAAP financial measures, specifically:
- Leverage Ratio: Defined as consolidated total debt to Adjusted EBITDA for trailing four quarters
- Adjusted EBITDA: A key liquidity measure used in credit agreement covenants
- Adjusted Free Cash Flow: Used to assess debt reduction capacity and development potential
The company emphasizes that noncompliance with financial covenants could trigger immediate debt repayment requirements. The filing includes forward-looking statements addressing potential risks such as infectious disease outbreaks, regulatory changes, staffing challenges, and cybersecurity threats that could impact future performance.